EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Incidental germline findings during comprehensive genomic profiling of pancreatic and colorectal cancer: single-centre, molecular tumour board experience

Michal Eid, Jakub Trizuljak, Renata Taslerova, Martin Gryc, Jakub Vlazny, Sara Vilmanova, Martina Jelinkova, Alena Homolova, Stepan Tucek, Jan Hlavsa, Tomas Grolich, Zdenek Kala und 2 weitere

Mutagenesis · 2025

DOI: 10.1093/mutage/geae014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mutagenesis, 2025. Verfasst von Michal Eid und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Hauptthemen laut MEDLINE: Germ-Line Mutation, Pancreatic Neoplasms, Colorectal Neoplasms, Incidental Findings. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Specific University Research, Ministry of Health, Czech Republic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multidisciplinary molecular tumor boards (MTB) are already well established in many comprehensive cancer centers and play an important role in the individual treatment planning for cancer patients. Comprehensive genomic profiling of tumor tissue based on next-generation sequencing is currently performed for diagnostic and mainly predictive testing. If somatic genomic variants are identified, which are suspected to be pathogenic germline variants (PGVs), MTB propose genetic counseling and germline DNA testing. Commonly used comprehensive genomic profiling approaches of tumor tissue do not include a matched germline DNA control. Therefore, the detection of PGVs could be only predicted based on the content of tumor cells (CTC) in selected tumor area (%) and variant allele frequency score (%). For conclusion, the role of a medical geneticist is essential in these cases. The overall prevalence of PGVs in patients with pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) is approximately 10%. In this single-center study, we present 37 patients with PDAC and 48 patients with CRC who were presented at MTB and tested using the large combined DNA/RNA sequencing panel. Content of tumor cells and variant allele frequency scores were evaluated in all tested patients. In case of suspicion of PGV and no previous genetic testing based on the standard guidelines, genetic counseling was recommended regardless of age, sex, and family history. In the PDAC subgroup, five patients were recommended by MTB for genetic counseling based on suspicious genetic findings. Based on a medical geneticist’s decision, germline DNA sequencing was performed in four of these cases, and all of them tested positive for PGV in the following genes: ATM, ATM, BRCA1, and BRCA2. In the CRC subgroup, no PGV was confirmed in the two patients genetically tested based on the MTB recommendations. Furthermore, we present data from our center’s registry of patients with PDAC and CRC who underwent genetic counseling and germline DNA testing based on the standard screening criteria. Our data confirm that comprehensive genomic profiling of tumor tissue can identify patients with hereditary forms of PDAC, who could remain unidentified by standard screening for hereditary forms of cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Germ-Line MutationPancreatic NeoplasmsColorectal NeoplasmsIncidental FindingsCarcinoma, Pancreatic DuctalHumansMaleFemaleMiddle AgedAgedAdultGenetic TestingHigh-Throughput Nucleotide SequencingGenomicsAged, 80 and overGene FrequencyGenetic Counseling

Stichwörter der Autor:innen

colorectal cancergermline variantsnext-generation sequencingpancreatic cancersomatic variants

Autor:innen und Institutionen

  • Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Department of Pathology, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Department of Surgery, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Department of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
  • Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

ORCID-Profile: Ondrej Slaby

Förderung

  • Specific University Research
  • Ministry of Health
  • Czech Republic
  • National Institute for Cancer Research

Zitieren

APA

Eid, M., Trizuljak, J., Taslerova, R., Gryc, M., Vlazny, J., Vilmanova, S., Jelinkova, M., Homolova, A., Tucek, S., Hlavsa, J., Grolich, T., Kala, Z., Kral, Z., & Slaby, O. (2025). Incidental germline findings during comprehensive genomic profiling of pancreatic and colorectal cancer: single-centre, molecular tumour board experience. Mutagenesis. https://doi.org/10.1093/mutage/geae014

Vancouver

Eid M, Trizuljak J, Taslerova R, Gryc M, Vlazny J, Vilmanova S, et al. Incidental germline findings during comprehensive genomic profiling of pancreatic and colorectal cancer: single-centre, molecular tumour board experience. Mutagenesis. 2025. doi:10.1093/mutage/geae014

BibTeX
@article{Eid2025,
  author = {Eid, Michal and Trizuljak, Jakub and Taslerova, Renata and Gryc, Martin and Vlazny, Jakub and Vilmanova, Sara and Jelinkova, Martina and Homolova, Alena and Tucek, Stepan and Hlavsa, Jan and Grolich, Tomas and Kala, Zdenek and Kral, Zdenek and Slaby, Ondrej},
  title = {Incidental germline findings during comprehensive genomic profiling of pancreatic and colorectal cancer: single-centre, molecular tumour board experience},
  journal = {Mutagenesis},
  year = {2025},
  doi = {10.1093/mutage/geae014}
}
Kostenlos starten →